Summary
On the basis that unbound concentration better correlates with response than total plasma or blood concentration, the inter- and intra-subject variability in the distribution of cyclosporin within blood and to plasma components was studied in renal transplant patients. Pharmacokinetic aspects were also studied.
Blood samples were analysed from patients who received the drug both by a 72-h i.v. infusion and orally (7 mg·kg−1 twice daily). Steady-state was reached within 18 h of starting the i.v. infusion; the plasma data were best fitted by a biexponential equation with half-times of 0.13–1.02 h and 4.3–13.9 h, associated with the two phases. The mean plasma clearance was 700 ml/min. Concentrations during the infusions measured by RIA and HPLC were comparable. Oral profiles showed rapid and extensive absorption. The peak plasma concentrations were 1460–1880 µg·l−1 and occurred 2–4 h after dosing, with bioavailability estimates of 41–113%. Concentrations measured by RIA were higher than by HPLC.
Blood-to-plasma concentration ratio measurements of cyclosporin at 37°C decreased with increasing plasma concentration and increased with haematocrit. Fraction unbound, measured by ultracentrifugation, was in the range 0.042–0.122 with an average of 0.068, and varied little in some patients but showed systematic changes with time in others. Cyclosporin binding was found to be related not only to the triglyceride but, more particularly, to the cholesterol-related lipoproteins in plasma. Monitoring cholesterol may be helpful in identifying patients with extremes in binding or with widely varying binding.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
The Canadian Multicentre Transplant Study Group (1983) A randomised clinical trial of Cyclosporin in cadaveric renal transplantation. N Engl J Med 309: 809–815
Kahan BD, van Buren CT, Lin SN, Ried M, LeGrue SJ (1982) Pharmacokinetics of cyclosporin A in renal allograft recipients. In: White DJG (ed) Cyclosproin A: Proc Int Conf Cyclosporin A, Cambridge, 1981. Elsevier Biomedical Press, Holland, pp 413–426
Stiller CR, Keown PA, Sinclair NR, Ulan RA (1982) Immune responses and pharmacokinetics in the human renal allograft recipient treated with Cyclosporin A. In: White DJG (ed) Cyclosporin A: Proc Int Conf on Cyclosporin A, Cambridge, 1981. Elsevier Biomedical Press, Holland, pp 379–386
Lokiec F, Poirier O, Gluckman E, Devergie A (1982) Cyclosporin A: Pharmacokinetic monitoring during treatment of graft-versus-host disease following bone marrow transplantation. In: White DJG (ed) Cyclosporin A: Proc Int Conf on Cyclosporin A, Cambridge, 1981. Elsevier Biomedical Press, Holland, pp 497–500
Morris PJ, French ME, Ting A, Frostick S, Hunniset A (1982) A controlled trial of Cyclosporin A in renal transplantation. In: White DJG (ed) Cyclosporin A: Proc Int Conf on Cyclosporin A, Cambridge, 1981. Elsevier Biomedical Press, Holland, pp 355–364
Holt DW, White DJG (1984) How to measure cyclosporin (Letter). Lancet 1: 228
Leyland-Jones B, Clark A, Kreis W, Dinsmore R, O'Reilly R, Young CW (1982) High pressure liquid chromatographic determination of Cyclosporin-A in human plasma. Res Commun Clin Pathol Pharmacol 37: 431–444
Bacigalupo A, Di Giorgio F, Frassoni F, Van Lint MT, Raffo MR, Gogiosol, Vialem, Marmont AM (1984) Cyclosporin A. Serum and blood levels in marrow graft recipients: Correlation with administered dose, serum creatinine and graft-versus-host disease. Acta Haematol (Basel) 72: 155–162
Calne RY (1985) Clinical transplantation summary. Transplant Proc 17: 1599–1603
Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O (1983) Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 15 [Suppl 1]: 2419–2421
Newburger J, Kahan BD (1983) Cyclosporine pharmacokinetics in man. Transplant Proc 15 [Suppl 1]: 2413–2415
Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR (1985) Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 38: 296–300
Legg B, Rowland M (1987) Cyclosporin A: Measurement of fraction unbound in plasma. J Pharm Pharmacol 39: 599–603
Carruthers SG, Freeman DJ, Koegler JC, Howson W, Keown PA, Laupacis A, Stiller CR (1983) Simplified liquid-chromatographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem 29: 180–183
Giegel JL, Ham AB, Clema W (1975) Manual and semi-automated procedures for measurement of triglycerides in serum. Clin Chem 21: 1575–1581
Jung DH, Biggs HG, Moorehead WR (1975) Colorimetry of serum cholesterol with use of ferric acetate/uranyl acetate and ferrous sulfate/sulfuric acid reagents. Clin Chem 21: 1526–1530
Gibaldi M, Perrier D (1982) Pharmacokinetics. Drugs and pharmaceutical sciences, vol. 15. Marcel Dekker, New York
Kates RE, Latini R (1984) Simple and rapid high-performance liquid chromatographic analysis of cyclosporine in human blood and serum. J Chromatogr 309: 441–447
Wideman CA (1983) Pharmacokinetic monitoring of cyclosporine. Transplant Proc 15 [Supp 2]: 3168–3175
Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of Cyclosporine in human renal transplantation. Transplant Proc 15: 446–453
Bertault-Pérès P, Maraninchi D, Carcassonne Y, Cano JP, Barbet J (1985) Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients. Cancer Chemother Pharmacol 15: 76–81
Burckart G, Starzl T, Williams L, Sanghri A, Garter C, Venkataramanan R, Zitelli B, Malatack J, Urbach A, Diver W, Ptachcinski R, Shaw B, Iwatsuki S (1985) Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 17: 1172–1175
Venkataramanan R, Ptachcinski RJ, Burckart GJ, Gray J, Van Thiel DH, Starzl TE (1985) Cyclosporine bioavailability in liver disease. Drug Intell Clin Pharm 19: 451
Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34: 715–718
Piafsky KM (1980) Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 5: 246–262
Pike E, Skuterud B, Kierulf P, Lunde PKM (1982) Significance of lipoproteins in serum binding variations of amitriptyline, nortripyline and quinidine. Clin Pharmacol Ther 32: 599–606
Burckart GJ, Ptachcinski RJ, Venkataramanan R, Iwatsuki S, Esquivel C, Van-Thiel DH, Starzl TE (1986) Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography. Transplant Proc 18, no. 6 [Suppl 5]: 129–136
Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Loertscher R, Lemaire M, Nussbaumer K, Niederberger W, Wood A (1983) Intravenous cyclosporine kinetics in renal failure. Clin Pharm Therap 34: 638–643
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Legg, B., Gupta, S.K., Rowland, M. et al. Cyclosporin: Pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. Eur J Clin Pharmacol 34, 451–460 (1988). https://doi.org/10.1007/BF01046701
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01046701